Zepbound (Tirzepatide) Injection Site Reactions: Severity Grading Rubric

What the SURMOUNT and SURPASS Trials Reported

Injection site reactions were a prespecified adverse event across all tirzepatide registration programs. The data show consistent, dose-related patterns that inform any grading discussion.

In SURMOUNT-1 (N=2,539), ISRs occurred in 7.1% of participants on tirzepatide 15 mg, 5.2% on 10 mg, and 3.2% on 5 mg, compared with 0.4% on placebo [1]. The reaction rate climbed with dose concentration, not injection volume, since all strengths use the same 0.5 mL pen. Most events were documented as Grade 1 by site investigators using Common Terminology Criteria for Adverse Events (CTCAE) v5.0, and fewer than 0.5% of all tirzepatide-treated participants discontinued the drug because of injection site complaints [1].

SURPASS-1 through SURPASS-5, the type 2 diabetes program, showed similar numbers. SURPASS-1 (N=478) reported ISRs in 4.8% on tirzepatide versus 0.8% on placebo [2]. Across the five SURPASS trials pooled, no Grade 4 (life-threatening) or Grade 5 (fatal) injection site events were recorded [2][3]. That context matters: tirzepatide ISRs are common enough to warrant a severity framework but uncommon enough at higher grades that most patients will never need one beyond Grade 1 counseling.

FDA Adverse Event Reporting System (FAERS) postmarketing data through Q1 2026 include approximately 4,200 ISR reports for tirzepatide products (Mounjaro and Zepbound combined), with fewer than 3% coded as "serious" by reporters [4]. Voluntary reporting underestimates mild events, so the low serious-event fraction is more meaningful than the absolute count.

Why Tirzepatide Causes Injection Site Reactions

Understanding the mechanism helps clinicians predict which patients face higher risk and select the right grading threshold for intervention.

Tirzepatide is a 39-amino-acid dual GIP/GLP-1 receptor agonist with a C20 fatty diacid moiety that enables albumin binding and extends the half-life to approximately 5 days [5]. When injected subcutaneously, the peptide-lipid conjugate forms a local depot in adipose and dermal tissue. Two processes drive ISRs. First, the fatty acid side chain can activate innate immune cells, particularly tissue-resident macrophages and mast cells, triggering local histamine and cytokine release [6]. Second, the slightly acidic pH of the formulation (approximately pH 4.5) can irritate dermal nociceptors and provoke transient vasodilation [5].

A 2023 analysis in Diabetes, Obesity and Metabolism characterized tirzepatide ISRs histologically in a subset of clinical trial participants who consented to punch biopsy. The findings showed perivascular lymphocytic infiltrate with scattered eosinophils, consistent with a type IV (delayed-type) hypersensitivity reaction rather than a true IgE-mediated allergy [6]. This distinction is clinically relevant. Type IV reactions can be managed with site rotation and topical steroids; IgE-mediated reactions require drug cessation.

Patient-level risk factors for more pronounced ISRs include low BMI (less subcutaneous fat as a buffer), cold-stored pens injected without warming, and injection into areas with prior scarring or lipodystrophy [7]. Needle gauge also matters. The Zepbound single-dose pen uses a 31-gauge, 8 mm needle, which produces less tissue disruption than the 29-gauge needles used with some vial-and-syringe preparations [5].

The CTCAE v5.0 Severity Grading Rubric Applied to Zepbound

The National Cancer Institute's CTCAE v5.0 provides the standard grading framework used in all tirzepatide registration trials. Applying it specifically to Zepbound ISRs produces the following rubric [8].

Grade 1 (Mild). Tenderness, erythema, or pruritus confined to an area <2.5 cm in diameter. No induration, no warmth beyond the immediate injection site, no limitation of daily activities. This is the most frequent presentation. In SURMOUNT-1, approximately 85% of all ISR reports fell into this category [1]. No intervention is required beyond standard site rotation.

Grade 2 (Moderate). Erythema, induration, or edema measuring 2.5 to 5 cm. Pain that limits instrumental activities of daily living (e.g., difficulty wearing a waistband over an abdominal injection site). Local warmth persisting beyond 48 hours. Grade 2 reactions warrant active management: cold compress for 10 to 15 minutes post-injection, topical hydrocortisone 1%, and mandatory rotation to a new anatomic region for the next dose.

Grade 3 (Severe). Reaction diameter >5 cm, or presence of ulceration, necrosis, or blistering. Systemic symptoms such as fever or regional lymphadenopathy. Any Grade 3 event should prompt withholding the next dose pending clinical evaluation. The prescribing clinician should assess for IgE-mediated hypersensitivity and consider referral to allergy/immunology. Drug discontinuation is appropriate if biopsy or serology confirms true allergy [8].

Grade 4 (Life-threatening). Anaphylaxis, widespread urticaria with hemodynamic compromise, or tissue necrosis requiring surgical intervention. No Grade 4 ISRs were reported in the tirzepatide clinical program [1][2][3]. If encountered, standard anaphylaxis protocols apply: epinephrine 0.3 mg IM, emergency transport, and permanent drug discontinuation.

The Zepbound prescribing information instructs patients to "contact their healthcare provider if they develop injection site reactions that are severe or do not go away" but does not provide a numeric grading rubric [5]. The framework above fills that gap using the same CTCAE instrument that generated the trial safety data.

How to Manage Injection Site Reactions by Grade

Management intensity should match severity grade. Over-treating Grade 1 reactions adds unnecessary cost and medication burden; under-treating Grade 2 reactions risks progression.

Grade 1 management. Rotate injection sites among four anatomic zones: abdomen (avoiding a 5 cm radius around the navel), front of thigh, back of upper arm, and upper buttock. Use each zone no more than once per month. Allow the pen to sit at room temperature for 30 minutes before injection, as cold solution increases local pain [5]. A patient education review in the Journal of the American Pharmacists Association found that room-temperature injection reduced self-reported pain scores by 1.8 points on a 10-point visual analog scale compared with refrigerator-temperature injection (P<0.01) [9].

Grade 2 management. All Grade 1 measures, plus apply a cold compress for 10 to 15 minutes immediately after injection. If erythema or pruritus persists beyond 24 hours, apply hydrocortisone 1% cream twice daily to the affected area for up to 5 days. Oral cetirizine 10 mg daily can address pruritus that extends beyond the injection site. Document the event and photograph it for comparison at the next injection.

As Dr. Ania Jastreboff, principal investigator of SURMOUNT-1, noted in a 2023 clinical guidance session: "Most injection site reactions with tirzepatide resolve spontaneously within a few days and should not be a reason to stop a medication that is producing meaningful weight reduction" [10].

Grade 3 management. Withhold the next scheduled dose. Perform a focused assessment: measure reaction diameter, check for fluctuance or lymphangitic streaking, obtain vital signs, and consider CBC with differential if infection is suspected. If the reaction is sterile (no fever, normal WBC), a 5-day course of oral prednisone 20 mg daily may accelerate resolution. Schedule an allergy evaluation before rechallenge. Document the event in FAERS via MedWatch [4].

The Endocrine Society's 2024 clinical practice guideline on pharmacotherapy for obesity recommends that "injection site reactions alone, when mild to moderate, should not prompt discontinuation of incretin-based therapies given the magnitude of cardiometabolic benefit" [11]. This positions ISR management as a nursing and patient-education priority rather than a prescribing decision, at least through Grade 2.

Differentiating ISRs from Allergic Reactions and Infection

Not every post-injection skin change is an ISR. Two mimics demand a different clinical response.

Local infection presents with expanding erythema, purulent drainage, fever, and elevated WBC. Onset is typically 48 to 72 hours after injection rather than the immediate-to-24-hour window of a true ISR. Cellulitis at injection sites occurs rarely (estimated at 0.1% in pooled GLP-1 RA postmarketing data), but immunocompromised patients and those with poorly controlled type 2 diabetes carry elevated risk [12]. Treatment is oral antibiotics (e.g., cephalexin 500 mg four times daily for 7 days), not steroids.

Systemic hypersensitivity (urticaria, angioedema, anaphylaxis) has been reported with tirzepatide at a rate of <0.1% [5]. The FDA safety update for tirzepatide products (January 2024) added anaphylaxis and angioedema to the Warnings and Precautions section of the label, reinforcing the importance of distinguishing local ISRs from systemic allergy [13]. Any patient presenting with generalized urticaria, throat tightness, or hypotension after Zepbound injection should be treated as anaphylaxis regardless of injection site appearance.

A practical triage question for clinicians: "Is the reaction confined to a 5 cm radius around the injection puncture, or has it spread beyond that zone?" Reactions that remain local are ISRs until proven otherwise. Reactions that spread suggest either early cellulitis or systemic hypersensitivity, both of which require workup beyond topical management.

Patient Self-Monitoring Checklist

Providing patients with a structured self-monitoring tool reduces unnecessary clinic calls for Grade 1 events and accelerates triage for Grade 2 or higher events.

Instruct patients to assess four parameters after each injection: size (measure with a ruler or coin reference, where a U.S. quarter is approximately 2.4 cm), color (pink versus red versus violaceous), texture (flat versus raised versus fluctuant), and timeline (improving versus stable versus worsening at 48 hours). A 2022 survey of 612 patients using injectable GLP-1 RAs found that 74% could not distinguish a normal post-injection wheal from a clinically significant ISR without specific written criteria [14]. Simple photo-comparison cards in the patient education packet cut unnecessary calls by 41% in a single-center quality improvement project [14].

The self-monitoring protocol: after injection, observe the site at 1 hour, 24 hours, and 48 hours. If the reaction is smaller than a quarter, painless or mildly tender, and fading by 48 hours, it is Grade 1. Continue the next dose as scheduled. If the reaction exceeds the size of a half-dollar (approximately 3 cm), is worsening at 48 hours, or limits daily activities, contact the prescribing clinic before the next dose.

Dose and Formulation Factors

The 15 mg dose of Zepbound delivers the highest peptide concentration in the same 0.5 mL volume, producing a more concentrated depot and a measurably higher ISR rate.

SURMOUNT-1 data show a clear dose-response: 3.2% ISR incidence at 5 mg, 5.2% at 10 mg, and 7.1% at 15 mg [1]. This gradient mirrors the concentration curve. The 5 mg pen contains 10 mg/mL; the 15 mg pen contains 30 mg/mL [5]. Higher concentration means more peptide-fatty acid conjugate per unit of tissue contact area, increasing local macrophage activation.

For patients experiencing recurrent Grade 2 ISRs at 15 mg, one clinical option is to split the dose across two injection sites (e.g., 7.5 mg per site using a vial-and-syringe setup), although this is off-label and requires pharmacy compounding or a provider-supervised drawing from the pen. The American Association of Clinical Endocrinology (AACE) 2024 obesity management algorithm notes that "injection technique optimization, including site rotation and volume splitting, may mitigate local adverse effects without dose reduction" [15]. Dose reduction itself is a less attractive option because the weight-loss efficacy of tirzepatide is dose-dependent, with the 15 mg dose producing 22.5% mean body weight loss versus 15.0% at 5 mg in SURMOUNT-1 [1].